Skip to content
#protein folding Open access

New thiazole/coumarin hybrids as EGFR inhibitors with potential VEGFR-2 inhibition (design, synthesis, biological evaluation, and dynamic stimulation)

Oct 2026 · RSC Advances · 0 citations · 51 references
Medicine

TL;DR

Two new series of coumarin–thiazole hybrids were designed and synthesized as EGFR/VEGFR-2 dual inhibitors and the most potent compounds (6a, 6h, and 9d) displayed remarkable inhibitory effectiveness against EGFR and VEGFR-2.

Abstract

Two new series of coumarin–thiazole hybrids (6a–i and 9a–h) were designed and synthesized as EGFR/VEGFR-2 dual inhibitors. Hybrids 6a–i demonstrated remarkable antiproliferative activities on different NCI-60 cell lines in a single-dose assay. The antiproliferative activities of the newly synthesized hybrids were evaluated against a panel of three human cancer cell lines (HepG2, HCT-116, and MCF-7). Compounds 6a, 6h, 9a, and 9d were the four most active hybrids. Herein, compound 6a was the most active antiproliferative agent among the 6a–i hybrids, with IC50 values ranging from 2.85 µM to 7.66 µM. At the same time, compound 9d was the most active antiproliferative agent among the 9a–h hybrids, with IC50 values ranging from 3.79 µM to 9.80 µM. Furthermore, hybrids 6a, 6h, 9a, and 9d expressed low cytotoxicity for the normal fetal lung WI-38 cells. Consistent with the mechanistic study, the most potent compounds (6a, 6h, and 9d) displayed remarkable inhibitory effectiveness against EGFR and VEGFR-2. Moreover, the most potent hybrid (6a) caused the upregulation of Bax, cytochrome c, and caspase-3 levels and downregulation of Bcl-2 levels. Molecular docking study for compounds 6a, 6h, 9a, and 9d agreed with the mechanistic results. Molecular docking into the ATP-binding site of EGFR (PDB: 1M17 and re-docking RMSD = 1.43 Å) and VEGFR-2 (PDB: 4ASD and re-docking RMSD = 1.67 Å) confirmed strong binding affinities for 6a (ΔG = −10.32 and −9.98 kcal mol−1, respectively) and 9d (ΔG = −10.23 and −9.87 kcal mol−1, respectively), consistent with their enzymatic inhibition profiles. To validate the dynamic stability of binding, 100 ns all-atom molecular dynamics (MD) simulations were performed for 6a and 9d in complex with EGFR, alongside erlotinib and the apo receptor. Compound 6a was carried forward into the 100 ns molecular dynamics simulations of five systems, comprising the apo receptor, the erlotinib complex and the complexes of 6a, 9d, and 9a. Ligand binding compacted the kinase by roughly 2.3 Å in the radius of gyration relative to the apo receptor and reduced Cα fluctuation across the fold. The total protein–ligand interaction energy ranked the four ligands in an order consistent with the enzymatic assay, yielding values of −69.6, −55.6, −50.6 and −41.7 kcal mol−1 for erlotinib, 6a, 9d and 9a against IC50 values of 0.14, 0.27, 0.378, and 2.94 µM, respectively. Furthermore, every pairwise separation exceeded twice the block-averaged standard error. Compound 6a was identified as the lead compound of the series.

Read PDF

Similar papers

Open access Sep 2026

Design, synthesis, and biological evaluation of quinolin-2-one/thiazole hybrids as multi-targeted antiproliferative agents inducing caspase-dependent apoptosis

Findings highlight compound 6b as a promising multi-kinase therapeutic scaffold for further targeted oncological optimization and highlighted that a 6-methyl substitution on the quinoline core, an unsubstituted N-1 position, and a bulky 3-phenyl group on the thiazole ring are key structural prerequisites for optimal an...

L. Al-Wahaibi, A. Y. Alzahrani, S. Bräse et al. · 0 citations
Open access Sep 2026

Design, synthesis, and molecular modeling of quinoline-linked diphenylpyrazoles as multitarget EGFR, VEGFR-2, and COX-2 inhibitors with anticancer, anti-inflammatory and apoptosis-inducing properties.

A new series of quinoline-diphenylpyrazole hybrids were rationally designed, synthesized, and biologically evaluated as potential EGFR/VEGFR-2/COX-2 inhibitors, supporting the proposed hybrid design strategy.

Abdelrahman Hamdi, Mohamed R. Elnagar, M. Hussein et al. · 0 citations
Open access Sep 2026

Design, Synthesis, In Vitro Biological Evaluation, and In Silico Studies of Novel Imidazo[4,5-b]Pyridine-Acrylonitrile-Based Derivatives as VEGFR-2 Inhibitors Against Breast Cancer and Hepatocellular Carcinoma.

Vascular endothelial growth factor receptor-2 (VEGFR-2) is a vital mediator of angiogenesis. Therefore, VEGFR-2 inhibition is considered a promising therapeutic target to combat cancer. In the present study, a series of 22 imidazo[4,5-b]pyridine-acrylonitrile-based derivatives was designed and synthesized. All compound...

Lamia W. Mohamed, Ahmed A. Saadeldin, Ayman B. Farag · 0 citations
Open access Sep 2026

Quinazolinone–diarylpyrazole hybrids as dual EGFR/COX-2 inhibitors: antiproliferative, mechanistic, and in silico studies

7f is identified as a promising lead displaying concurrent EGFR and COX-2 inhibitory activity together with pronounced antiproliferative effects, consistent with its experimentally observed dual inhibitory activity.

Abdullah Alkhammash, B. A. Saleem, Khulood H. Oudah et al. · 0 citations
Open access Sep 2026

Synthesis, anti-proliferative evaluation, DFT, in silico ADME and molecular modeling studies of novel imidazolones as potential EGFR inhibitors

Findings identify bromophenyl-substituted imidazolone derivatives, particularly compound 5, as promising anticancer lead candidates, while suggesting EGFR as a plausible molecular target.

Mohamed H. Hekal, Mohamed Abdel-Megid, Mostafa E. Salem et al. · 0 citations
Oct 2026

Benzodiazepine-based N,S-heterocyclic hybrids as multi-target therapeutic candidates for cancer and inflammation: enzymatic evaluation, cellular mechanistic studies, in vivo anti-inflammatory assessment, and computational investigations.

A series of eleven novel benzodiazepine-based N, S-heterocyclic hybrids incorporating thienothiazine and thienopyrimidine scaffolds was designed, synthesized, and characterized by spectroscopic and analytical techniques. Compounds 4 and 6 showed favorable selectivity against HCT-116 and MDA-MB-231 cells relative to nor...

Hagar S. El-Hema, M. A. Abed, M. A. Hawata et al. · 0 citations

Related blog posts

Google DeepMind Blog Sep 30, 2026

Introducing SynthID Bio

Proof of concept for watermarking AI-generated proteins while preserving biological function.

MIT News · Artificial Intelligence Aug 27, 2026

Looking beyond natural sequences

A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.